Tuberculosis Infection Clinical Trial
Official title:
Tuberculosis Infection in Children Visiting Friends and Relatives in Countries With High Incidence of Tuberculosis: a Study Protocol
In countries with a low incidence of Tuberculosis (TB), the incidence remains higher among the immigrant population than among the autochthonous population beyond the first years after arrival in the host country. In addition, at a pediatric level, most cases are produced in immigrant children and the children of immigrants. This persistence of a greater incidence in the immigrant population might, in part, be explained by the increase in exposure to Mycobacterium tuberculosis during trips to their country of origin to visit friends and relatives (VFRs). The objectives of the study are to estimate the risk of latent infection by M. tuberculosis (LTBI)/TB in children VFRs and the factors associated with this risk. The investigators will also study the behavior of the diagnostic tests. This project will be carried out in collaboration with 21 primary health care centers and 5 hospitals in Catalonia.
A prospective study will be carried out. The study subjects are children under 15 years of age, which are children of immigrants and born or not in Spain, who travel to VFRs to countries with an elevated incidence of TB (> 40 cases/100,000 inhabitants). A sample size of 492 children was estimated. Children will be recruited during a programmed visit to a traveler health clinic or a primary care center, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit in which a questionnaire will be completed with epidemiological and clinical data, an a TST and QFT-Plus test will be performed. The rate of incidence of LTBI will be estimated per individual/month and person/year per country visited and by age group. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Completed |
NCT04545164 -
Computer Aided Screening for Tuberculosis in Low Resource Environments
|
N/A | |
Recruiting |
NCT05766267 -
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
Enrolling by invitation |
NCT04988984 -
Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
|
||
Recruiting |
NCT04148053 -
Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
|
||
Recruiting |
NCT01689831 -
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
|
Phase 2 | |
Completed |
NCT05945498 -
Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
|
Phase 1 | |
Not yet recruiting |
NCT06352970 -
Effects of Tuberculosis Infection on Development and Function of the Placenta
|
||
Recruiting |
NCT04575519 -
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
|
Phase 2 | |
Recruiting |
NCT05413551 -
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
|
Phase 1 | |
Recruiting |
NCT03941210 -
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
|
||
Completed |
NCT04494516 -
Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
|
||
Withdrawn |
NCT03265977 -
A Phase II Study of H56:IC31 in Healthy Adolescents
|
Phase 2 | |
Recruiting |
NCT05069688 -
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
|
Phase 1 | |
Suspended |
NCT05330884 -
BCG Revaccination in Children and Adolescents
|
Phase 3 | |
Recruiting |
NCT05342064 -
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
|
N/A | |
Recruiting |
NCT05236452 -
Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection
|
N/A | |
Recruiting |
NCT05443178 -
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
|
Phase 1 | |
Recruiting |
NCT05122026 -
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
|
Phase 1/Phase 2 |